Attributes | Values |
---|
rdf:type
| |
description
| - wetenschappelijk artikel (nl)
- article scientifique publié en 2019 (fr)
- im November 2019 veröffentlichter wissenschaftlicher Artikel (de)
- scientific article published on 01 November 2019 (en)
- artículu científicu espublizáu en payares de 2019 (ast)
- գիտական հոդված հրատարակված 2019 թվականի նոյեմբերի 1-ին (hy)
- наукова стаття, опублікована 1 листопада 2019 (uk)
|
publication date
| |
publication date
| |
cites work
| |
cites work
| - Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer
- Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents
- Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial.
- Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncol
- Improved outcomes with dose-dense paclitaxel-based neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma
- Changes in ovarian cancer survival during the 20 years before the era of targeted therapy.
- Efficacy and safety of dose-dense paclitaxel plus carboplatin as neoadjuvant chemotherapy for advanced ovarian, fallopian tube or peritoneal cancer.
- Expression of programmed cell death ligand 1 and immune checkpoint markers in residual tumors after neoadjuvant chemotherapy for advanced high-grade serous ovarian cancer
- Trials in progress: IMagyn050/GOG 3015/ENGOT-OV39. A Phase III, multicenter, randomized study of atezolizumab versus placebo administered in combination with paclitaxel, carboplatin, and bevacizumab to patients with newly-diagnosed stage III or stag
|
author name string
| |
author name string
| |
rdfs:label
| - A phase II study of neoadjuvant chemotherapy plus durvalumab and tremelimumab in advanced-stage ovarian cancer: a Korean Gynecologic Oncology Group Study (KGOG 3046), TRU-D (en)
- A phase II study of neoadjuvant chemotherapy plus durvalumab and tremelimumab in advanced-stage ovarian cancer: a Korean Gynecologic Oncology Group Study (KGOG 3046), TRU-D (nl)
|
skos:prefLabel
| - A phase II study of neoadjuvant chemotherapy plus durvalumab and tremelimumab in advanced-stage ovarian cancer: a Korean Gynecologic Oncology Group Study (KGOG 3046), TRU-D (en)
- A phase II study of neoadjuvant chemotherapy plus durvalumab and tremelimumab in advanced-stage ovarian cancer: a Korean Gynecologic Oncology Group Study (KGOG 3046), TRU-D (nl)
|
name
| - A phase II study of neoadjuvant chemotherapy plus durvalumab and tremelimumab in advanced-stage ovarian cancer: a Korean Gynecologic Oncology Group Study (KGOG 3046), TRU-D (en)
- A phase II study of neoadjuvant chemotherapy plus durvalumab and tremelimumab in advanced-stage ovarian cancer: a Korean Gynecologic Oncology Group Study (KGOG 3046), TRU-D (nl)
|
author
| |
author
| |
title
| |
title
| - A phase II study of neoadjuvant chemotherapy plus durvalumab and tremelimumab in advanced-stage ovarian cancer: a Korean Gynecologic Oncology Group Study (KGOG 3046), TRU-D (en)
|
page(s)
| |
page(s)
| |
instance of
| |
instance of
| |
main subject
| |
main subject
| |
PubMed ID
| |
PubMed ID
| |
PubMed ID
| |
published in
| |
published in
| |
issue
| |
volume
| |
issue
| |
volume
| |
DOI
| |
DOI
| |
DOI
| |
copyright license
| |
copyright status
| |
copyright license
| |
copyright status
| |
PMCID
| |
PMCID
| |
is about
of | |
is cites work
of | |
is cites work
of | |